title: Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
authors: Duke University Medical Center, Durham, NC, USA.
authors: Emil
authors: E
authors: Lou
authors: Scott
authors: S
authors: Turner
authors: Ashley
authors: A
authors: Sumrall
authors: David A
authors: DA
authors: Reardon
authors: Annick
authors: A
authors: Desjardins
authors: Katherine B
authors: KB
authors: Peters
authors: John H
authors: JH
authors: Sampson
authors: Henry S
authors: HS
authors: Friedman
authors: James J
authors: JJ
authors: Vredenburgh
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D000077204:Temozolomide
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide